Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding ilixadencel improved outcomes in metastatic renal cell carcinoma

Publish date:: February 10, 2020

Key clinical point: Adding ilixadencel to sunitinib therapy improved outcomes versus sunitinib monotherapy in patients with newly diagnosed synchronous metastatic renal cell carcinoma.

Major finding: The confirmed overall response rate was 42% with ilixadencel plus sunitinib and 24% with sunitinib monotherapy.

Study details: A randomized, phase 2 study of 70 evaluable patients.

Disclosures: This study was funded by Immunicum. Dr. Lindskog disclosed relationships with Pfizer, Bristol-Myers Squibb, and Ipsen.

Citation:

Lindskog M et al. ASCO-SITC 2020, Abstract 11.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Renal Cell Carcinoma

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Fear of recurrence highly prevalent in RCC survivors,

Risk factors for severe immune-related AEs identified,

Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC,